Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 2.
THYROLAR-0.25 vs THYROLAR-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
None Documented
None Documented
Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone.
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%.
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone